Member Info for Mozax

This is looking good for a top up, who’s going to go first?

Hilarious that the MM’s put a 35% rise on open, having already gapped it up !

I’ve plopped 9K at 45p, 15p less than they’re paying in the US. Happy days.

Watch Randy Baron on YouTube discuss Renalytix, 2 years but very very informative.

Interesting that it was sold off here down to 38p & open this morning is 54p on the Bid.

Dangerous to sell out when the US still had 6 hours to run.

What are you talking about? This is dual listed and the price will correct itself, if you can buy quickly enough in the morning!!

Creeping up.

Let’s see how this goes over the next few sessions.

Happy to continue adding lower, research suggest potentially very valuable Company in the making.

Can you give it a rest.

Research the Company, and then you’ll understand how easy it is to ignore the noise & hold.

Bid jumped 5p, being played big time.

850M people worldwide.

Investigate RENX properly.

Only disruptive diagnostic Company in this space.

Massive potential beyond short term share price volatility.

Furthermore, people should research who Christopher Mills is. Apart from Non Exec Chairman of Renalytix.

For the lazy ones, he’s Chief Investment Officer at Harewood Capital LLP, look up what they do.

There are under 100M shares in issue and he’s taken over 10%.

Interesting that the Icahn School of Medicine, New York holds 15%. Look at the hospitals it manages.

Raised in a private placement 10th Feb 2023, RNS 6203P.

Christopher Mills, Non exec Chairman Bought 345, 375 at 90 pence, and holds over 10 million shares.

Big shake and early profit takers out, moving back up already, remember, 15 min delay here.

I’m looking at a 5 year graph for Renalytix PLC on the NASDAQ and seeing a high of $31.5 USD, end of MAY 2021.

That’s over £25.00 a share.

No speeding ticket as the news is out there, Medicare draft decision on lead product.

The US investors obviously ahead of the game on this news.

Closed $1.25s, so around 100p.

Note highs of $4.00 July 2023.

All holders are underwater here atm, so anyone selling is crystallising a loss.

I believe this will rocket on the next update with news of rapid user & revenue growth.

“Everything is in place for scalability”

Remember that.

That’s the risk for those opting to be out over the weekend, a big gap up on Monday after a w/e surge in BTC.

Don’t be surprised if you get a stiff foot.

Very interesting that the UK & Belgium took 20% of the ED market on a soft launch, ‘ which even took Futura by surprise’.

Perhaps the ED market is bigger than 1 in 5 men, which isn’t surprising as blokes really aren’t likely to admit to ‘performance issues’ ….which leads me to conclude that the only ‘over the Counter’ solution in Eroxon is proving deeply popular, as buyers can make a purchase without an ‘interview’ for such a product.

So, extrapolating potential Global market share from initial sales becomes very interesting.

Within the next 2 months or so Eroxon will rollout in 10 Countries, mainly Europe but also including Saudi Arabia.

I understand that Mexico & Brazil is in the mix, but I need to research this further, I note Barder mentioned they were in discussions over these Countries last Autumn.

In a recent Interview he mentioned they were ‘moving forward’ in Asia.

In the background we have Haleon working towards launch and rollout across the USA.

So, if 2023 was transformational, 2024 is going to be phenomenal.

I’m not going to put figures to my thoughts at this stage but I do believe Futura is going to announce some stratospheric revenues in 2025.

How far forward will the market start to look?

I should add that it’s more than coincidental that “Stifel” have been appointed as joint brokers with immediate effect as announced on the 6th February 2024.

“Stifel” are specialists in M&A…….